Managing patients with high risk breast lesions

Sarah Anwar, MDLinx

San Antonio Breast Cancer Symposium 2017

San Antonio, Texas, United States | December 05-09, 2017

Amy C. Degnim, MD, professor of surgery, Mayo Clinic, Rochester, MN, discusses the different management strategies for lesions that put patients at increased risk for breast cancer.

“There’s no right or wrong choice in managing risk, it’s really just a discussion between the provider and patient to understand what their risk is, and understand the options for managing that risk and figuring out what is the best fit for that patient.”

In some cases, excising the lesion is the best course of action. However, it is important to gauge the risk of cancer so as to avoid unnecessary excisions.

All Interviews

From this Conference

1:11

Breast imaging can predict cancer recurrence
At the 2018 Best of SABCS-NY, Sheldon Feldman, MD, FACS, chief of breast surgery and breast surgical oncology, Montefiore-Einstein Cancer Center, New York, director of breast...
Sheldon Feldman, MD, FACS
0:52

Value of chemotherapy for patients with locoregional breast cancer recurrence
In patients with locoregional recurrence of breast cancer, the effects of chemotherapy are varied, depending on whether they have hormone receptor positive or hormone receptor...
William Gradishar, MD
1:50

Tumor types, immune response, and radiotherapy
One of the most exciting areas of study currently being conducted in breast cancer is the potential of radiation therapy to convert tumors into an in situ vaccine. Silvia...
Silvia Formenti, MD

3:02

How to approach your patients to improve adherence to therapy
With recent approvals for new oral mTOR and CDK 4/6 inhibitors, patients with cancer are more responsible for treatment adherence, and it is important to keep the lines of...
Angela DeMichele, MD, MSCE
2:02

Breast cancer: Mortality rates in men versus women
When we think of breast cancer, rarely do we consider the male patient, and it might be because “men are at a dramatically lower risk for breast cancer than...
Amy C. Degnim, MD
2:14

Breast cancer: Where we were and how far we’ve come
Over the past few decades, great progress has been made in the field of breast cancer, according to Tatiana Prowell, MD, breast cancer scientific liaison, FDA Oncology Center...
Tatiana Prowell, MD

This activity is not sanctioned by, nor a part of, the San Antonio Breast Cancer Symposium 2017.